MCA stability tool

Check whether tablets and capsules are suitable for a multi-compartment compliance aid (MCA), and build a list to print.

Browse medicines A to Z

A (medicines beginning with A) B (medicines beginning with B) C (medicines beginning with C) D (medicines beginning with D) E (medicines beginning with E) F (medicines beginning with F) G (medicines beginning with G) H (medicines beginning with H) I (medicines beginning with I) K (medicines beginning with K) L (medicines beginning with L) M (medicines beginning with M) N (medicines beginning with N) O (medicines beginning with O) P (medicines beginning with P) Q (medicines beginning with Q) R (medicines beginning with R) S (medicines beginning with S) T (medicines beginning with T) U (medicines beginning with U) V (medicines beginning with V) W (medicines beginning with W) X (medicines beginning with X) Y (medicines beginning with Y) Z (medicines beginning with Z)

Medicines beginning with B

Bosentan

Bosentan 62.5mg tablets

No stability information

Stability notes for Bosentan 62.5mg tablets

There are no stability notes for this medicine.

Suppliers

Bosentan 62.5mg tablets (Accord-UK Ltd)
Bosentan 62.5mg tablets (Cipla EU Ltd)
Bosentan 62.5mg tablets (Viatris UK Healthcare Ltd)

Bosentan 125mg tablets

No stability information

Stability notes for Bosentan 125mg tablets

There are no stability notes for this medicine.

Suppliers (4) of Bosentan 125mg tablets
Bosentan 125mg tablets (Accord-UK Ltd)
Bosentan 125mg tablets (Cipla EU Ltd)
Bosentan 125mg tablets (Milpharm Ltd)
Bosentan 125mg tablets (Viatris UK Healthcare Ltd)

What the ratings mean

Compatible
Suitable for use. Keep in MCA for shortest possible time: no more than 5 weeks for non-airtight; 8 weeks for airtight. Use likely to be off-label.
Use with caution
Suitable with mitigations. Keep in MCA for shortest possible time: no more than 5 weeks for non-airtight; 8 weeks for airtight. Use likely to be off-label and supported by limited data.
Incompatible
Medicines under this category are not suitable for use in MCAs.
No stability information
These medicines have not been reviewed by SPS.